Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >-30 days and ≤90 days from conception (SHORT_EXP), and describing newborns' outcomes.
Landi, D., Bovis, F., Grimaldi, A., Annovazzi, P.o., Bertolotto, A., Bianchi, A., et al. (2022). Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, jnnp-2022-329657 [10.1136/jnnp-2022-329657].
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
Landi, Doriana
;Bianchi, Alessia;Centonze, Diego;Mataluni, Giorgia;Marfia, Girolama Alessandra
2022-09-30
Abstract
Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >-30 days and ≤90 days from conception (SHORT_EXP), and describing newborns' outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
jnnp-2022-329657.full.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
